Epic Sciences

Press Releases

06.24.2016

Epic Sciences introduces sensitive HRD liquid biopsy test for PARP inhibitor clinical trials.

Epic Sciences unveiled a liquid biopsy test that more sensitively detects cancers susceptible to PARP inhibitors by targeting homologous recombination deficiency (HRD) in individual circulating tumor cells (CTCs).

06.04.2016

Presence of AR-V7 in circulating tumor cells validated as predictive biomarker for advanced prostate cancer treatment by Memorial Sloan Kettering and Epic Sciences.

New Publication: JAMA Oncology 2016.

03.04.2016

Epic Sciences to present at Molecular Medicine Tri-Con 2016.

Epic Sciences, Inc., announced today that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the Molecular Medicine Tri-Con 2016, taking place at the Moscone Convention Center, San Francisco.

01.28.2016

Avera Medical Group and Epic Sciences collaborate on cancer precision medicine clinical trials.

Epic Sciences, Inc. and Avera Medical Group announced today a collaboration on feasibility studies to better understand the effectiveness of personalized cancer treatments as part of novel ovarian and breast cancer clinical trials.

01.11.2016

Epic Sciences receives CAP accreditation.

Epic Sciences announced today that they have received notice of their accreditation from the College of American Pathologists (CAP) for its San Diego laboratory.

01.04.2016

Circulating tumor cells linked with treatment resistance and response in prostate cancer patients.

Research teams at Memorial Sloan Kettering Cancer Center and Epic Sciences have found that greater diversity among circulating tumor cells (CTCs) in the blood of advanced prostate cancer patients predicts not only shorter overall survival, but also the development of resistance to key anti-androgen therapies.

12.11.2015

Epic Sciences enters into 35th pharma collaboration to advance companion diagnostics for new targeted therapeutics.

Epic Sciences, a private biotech company that develops novel diagnostics to personalize and advance the treatment and management of cancer, announced today that it has signed its 35th collaboration agreement with pharmaceutical companies.